Kornimate/medical-research-clean huggingface dataset:
peroperative effect of regional anesthesia in hip surgery

Conditions: Analgesia

Summary: a total of 120 patients scheduled for surgical operation due to hip fracture were divided into two randomized groups. the first group received pericapsular nerve group (peng) block, while the second group received lumbar erector spinae plane (l-esp) block prior to the surgery. subsequently, all patients were positioned in the lateral decubitus position before spinal anesthesia and compared in terms of anesthesia effectiveness through pain scores.


Eligibility criteria:
inclusion criteria: - american society of anesthesiologists(asa) 2-3 patients undergoing surgery due to hip fracture. exclusion criteria: * patients in whom regional anesthesia is contraindicated. * patients who are unable to communicate. * patients with a known allergy to local anesthetics. * patients with organ failure.
axillary versus primary breast approach for second-stage breast reconstruction

Conditions: Breast Neoplasm Female; Breast Reconstruction; Wound Complication

Summary: the goal of this clinical trial is to compare the safety of axillary or primary breast approach for second-stage operation in expander-implant breast reconstruction for breast cancer patients. the main question it aims to answer are: 1. if the wound related events, including wound dehiscence, infection, delayed healing is significant less often in patients receiving second stage operation via axillary approach compared with primary breast approach; 2. if the aesthetic outcome is comparable between patients receiving different approach for second stage operation. to answer these questions, the breast cancer patients have received nipple-sparing or skin-sparing mastectomy and had breast tissue expander insertion via breast incision, will be prospectively recruited, and randomized into two groups while receiving implant exchange operation: (1) operate via axillary incision; (2) operate via primary breast incision.


Eligibility criteria:
inclusion criteria: * age 18 + (inclusive) * female * invasive breast cancer or ductal carcinoma in situ was confirmed by preoperative pathology * ssm/nsm (skin sparing/nipple and areola sparing mastectomy) combined with expander implantation has been performed within a year * an incision on the surface of the breast is used to place an expander in the first-stage surgery * there is no clinical or radiological evidence of distant metastasis * expander removal combined with prosthesis implantation is planned * able and willing to sign an informed consent exclusion criteria: * the first ssm/nsm combined expander implantation was performed via axillary approach * patients participate in other clinical trial, which could potentially affect their participation in this trial * adjuvant radiotherapy was planned post-operation * patient who is pregnant and lactating * the expander is not sufficiently expanded pre-surgery (does not reach more than 90% of its volume)
assessment of 4d 18f-fdg pet-ct in radiotherapy for non small cell lung cancers

Conditions: Lung Cancer; Non-small-cell Lung Carcinoma

Summary: computed tomography (ct) images, used for radiotherapy planning, are often caught out in lung target volumes delineation because of their inability to differentiate between neoplasia, inflammation and atelectasia. positron emission tomography (pet) is a new functional imaging modality and is currently used in the diagnosis and the staging of lung cancers. the aim of this study is to evaluate the impact of 4d 18f-fdg-pet-ct on radiotherapy planning for lung cancers.

many pet studies have been interested in lung radiotherapy volumes definition, however lacking any standardisation. effectively, the use of pet images is difficult because of the poor image quality resulting from noise and partial volume effects induced blurring. moreover, due to the long duration of pet acquisitions, respiratory motions are inevitable and result in artifacts in the pet images affecting the volumes and contrast of the tumour: tumours may appear larger while their activity can be lower. to overcome these limitations, we propose to use a 4d pet-ct, ie a pet-ct acquisition system synchronized with respiration in order to compare ct-simulation target volumes and pet target volumes after application of different approaches for partial volume effect correction, respiratory motion correction and automatic segmentation method of functional volumes. for this purpose, patients with a non small cell lung cancer and having to be treated with radiotherapy or radio-chemotherapy underwent ct-simulation and 4d pet-ct in radiotherapy treatment position. the target volumes and the dosimetries obtained with both modalities were compared.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * patients with unresectable non small cell lung cancer having to be treated with radiotherapy or radio-chemotherapy exclusion criteria: * neo-adjuvant treatment * patient treated previously with thoracic radiation * patient unable to support 4d pet-ct * pregnant or breast-feeding woman

Keywords: positron emission tomography computed tomography lung cancer
double-blind trial of buspirone for the treatment of anxiety in youth with autism spectrum disorders

Conditions: Autism Spectrum Disorder (ASD)

Summary: the main objective of this exploratory 8 week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders. the study results will be used to generate hypotheses for a larger randomized controlled clinical trial with explicit hypotheses and sufficient statistical power.


Eligibility criteria:
inclusion criteria: * male or female participants between 6 and 17 years of age. * fulfills diagnosis of autism spectrum disorders by meeting dsm-iv-tr pdd diagnostic criteria of autistic disorder, asperger's disorder, or pdd-nos as established by clinical diagnostic interview. * participants with a score of ≥60 on the anxiety/depression subscale of child behavior checklist (cbcl) and cgi-anxiety severity of ≥4. * subjects can be on psychotropic drugs if they have been on the medication for at least 4 weeks prior to initiating study treatment and if they are on a stable dose. * subjects with disruptive behavior disorders, mood, or psychosis will be allowed to participate in the study provided they do not meet any exclusionary criteria. exclusion criteria: * mental retardation (i.q. \<70) * dsm-iv-tr pdd diagnosis of rett's disorder, and childhood disintegrative disorder. * history of active seizure disorder (eeg suggestive of seizure activity and/or history of seizure in last 1 month). * subjects with a medical condition or treatment that will either jeopardize subject safety or affect the scientific merit of the study, including: pregnant or nursing females, organic brain disorders, uncorrected hypothyroidism or hyperthyroidism, clinically significant abnormalities on ecg (e.g. qt prolongation, arrhythmia), history of renal or hepatic impairment. * clinically unstable psychiatric conditions or judged to be at serious suicidal risk. * history of substance abuse (except nicotine of caffeine) within past 3 months or urine drug screen positive for substances of abuse. * any other concomitant medication with primary central nervous system activity other than stable regimens for \>2 weeks. * a non-responder or history of intolerance to buspirone, after treatment at an adequate dose and duration as determined by the clinician.

Keywords: buspirone buspar autism spectrum disorders pervasive developmental disorders children adolescents anxiety
fungiscope - a global emerging fungal infection registry

Conditions: Invasive Fungal Disease

Summary: the objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.

the specific objectives are: 1. to determine the fungal species causing invasive fungal infection in different parts of the world. 2. to determine the clinical pattern of disease and document procedures performed for confirmation of the diagnosis. 3. to describe the therapeutic regimens used and their efficacy. 4. to share clinical isolates among the contributors of fungiscope. 5. to develop molecular biology tools for identification of strains in histopathologically proven invasive fungal infection.

Eligibility criteria:
inclusion criteria: * cultural, histopathological, antigen or dna evidence of invasive fungal infection exclusion criteria: * infection due to candida spp., cryptococcus neoformans, pneumocystis jiroveci * endemic fungal infection such as coccidioidomycosis or histoplasmosis * colonisation or other non-invasive infection

Keywords: invasive fungal infection web-based registry
the injection-related infections (iris) program

Conditions: Peer Support; Injection-related Infections; Infections; People Who Infect Drugs (PWID)

Summary: people who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. the injection-related infections (iris) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. iris is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. this program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. the investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). the investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. the investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.


Eligibility criteria:
inclusion criteria: * age 16 or older * able to provide informed consent * presenting with a confirmed or suspected injection-related infection (including skin and soft tissue infections, osteomyelitis, infective endocarditis, hepatitis c, hiv, etc) * history of injection drug use within 3 months of recruitment * lives in hamilton, ontario exclusion criteria: -
cohort study on the age-related macular degeneration: incidence and research for predisposing factors

Conditions: Elderly French Population; Age-related Macular Degeneration

Summary: age-related macular degeneration (amd) is the most cause of blindness in the industrialised countries. there are few epidemiological studies on the incidence of this disease. studying the incidence of amd in an elderly french population and identifying the predisposing factors is very important to allow a major advance in the epidemiological knowledge of amd. this study will contribute to the identification of the clinical, genetic and modifiable parameters associated at the risk of developing amd. this could result in means prevention as well as in the identification of subjects as high risk of amd

age-related macular degeneration is the most cause of blindness in the industrialised countries. there are few french epidemiological data on this disease. worldwide, studies have included a small number of very old subjects. thus, it is important to estimate the amd incidence in an elderly french population, in order to evaluate more precisely the number of cases in the french population. besides, some clinical, genetic and modifiable parameters predisposing to the amd are under study. the aim of the eclair project is to study the 8-year incidence of amd in an elderly french population and to identify the predisposing factors. it is based on an existing cohort study (alienor) in which some clinical, genetic and modifiable data were collected at baseline, 2 and 4 years. it is the only cohort study performed in france in this field since fifteen years in parallel with another one performed in dijon according to the same methodology. it is important to extend the study to 8 years in order to have a sufficient statistical power for the identification of predisposing factors. in the eclair study, there is no treatment. the subjects will be followed during 2 years (6 and 8 years after baseline of the alienor study). the visit 1 (a0) will be the inclusion visit where the subjects will sign the inform consent and will perform ophthalmological examinations. the subjects will come back 2 years later for the visit 2 (a2). in this second visit, the ophthalmological examinations will be the same that is: measure of clinical parameters, measurement of visual acuity exams, retinophotography,spectral domain optical coherence tomography (sd-oct), intraocular pressure, retinal imaging (optomap), axial length (iol master)

Eligibility criteria:
inclusion criteria: * subject participating in the study alienor * affiliated to a social security * consent signed by the patient and the investigator exclusion criteria: - health incompatible with one hour and a half ophthalmic examination

Keywords: amd epidemiology risk factors cohort study
incentive spirometer as a visual feedback in children with spastic cerebral palsy

Conditions: Cerebral Palsy, Spastic

Summary: objective: to compare the effects of incentive spirometer as a visual feedback versus deep breathing via mirror mediated therapy on pulmonary function in children with spastic cerebral palsy. to determine the effects of incentive spirometer as a visual feedback versus deep breathing via mirror mediated therapy on sleep and quality of life in children with spastic cerebral palsy.


Eligibility criteria:
inclusion criteria: * participants falling in this category would be recruited into the study. * spastic diplegic, age above 5. * according to modified ashworth scale, moderate spasticity 1 to 3. * adequate cognition (will be assessed by using mmse scale) in order to follow the instructions to use incentive spirometry and also able to comprehend single verbal command for breathing. * able to attend all sessions. (mentally and physically capable of attending session). * able to sit with support. exclusion criteria: * participant falling in this category would be excluded of the study. * patients with any respiratory or cardiac disease that can affect their respiratory function. * patients with beta blockers or bronchodilators. * children with any cognitive impairment who are unable to follow instructions. * children with bone deformities, such as scoliosis or kyphosis. * children with any sort of auditory and visual defects.
the effect of virtual reality glasses on pain level and hemo-dynamic variables after open heart surgery

Conditions: Pain; Hemodynamic Instability

Summary: in this study, between 1 january 2025 - 1 june 2025, who met the inclusion and exclusion criteria, a total of 82 patients who are on the 2nd or 3rd day after the surgery and who are hospitalized in the cardiovascular surgery intensive care clinic will be recruited.

the patient will be put on virtual reality glasses five minutes before the chest tube is removed. afterwards, it will continue to be watched while the tube is taken and virtual reality glasses will be watched for another five minutes. pain level and hemodynamic variables will be checked before, during, and 15 and 30 minutes after virtual reality glasses are watched. the participants in the control group will receive routine treatment and care, and their data will be collected at the same time as those in the study group. hemodynamic variables will be monitored and recorded on the monitor. virtual reality glasses application is a method without any side effects. during the research, any adverse condition (vision problem, nausea, dizziness, etc.) related to the use of virtual glasses will be observed by the researcher. since virtual reality glasses will be used in another patient after being used on one patient, disinfection will be made in line with the company's recommendations, taking into account the pandemic conditions. throughout the application, feedback will be received from the patients by the researchers.

Eligibility criteria:
inclusion criteria: * agreeing to participate in the research (signing the informed consent form), * conscious and cooperative, * stable hemodynamic status, * speaks and understands turkish, * over 18 years old, * on the 2nd and 3rd day after open heart surgery, * having chest tube, * no sensitivity or trauma in the area (for the study group) where the virtual reality glasses will be applied, * no active covid-19 infection, * patients without any psychiatric diagnosis exclusion criteria: * agreeing to participate in the research (signing the informed consent form), * not conscious, * not cooperative * unstable hemodynamic status, * speaks and understands turkish, * who are under the age of 18, * on the 0th or 1st day after surgery, * no chest tube, * has sensitivity or trauma in the area (for the study group) where the virtual reality * active covid-19 infection, * patients with a psychiatric diagnosis

Keywords: pain virtual reality glasses open heart surgery hemodynamic
mri-volumetry in the evaluation of shunt treatment for hydrocephalus

Conditions: Hydrocephalus, Normal Pressure

Summary: this randomized, double-blinded, cross-over study aim to evaluate the effects of shunt treatment in idiopathic normal pressure hydrocephalus (inph) by measuring cerebral ventricular volume and clinical symptoms at different shunt opening pressures. further, proteins in the cerebrospinal fluid (csf) will be compared before and after shunt surgery.

the participants are evaluated before surgery and one month, two months, three months and three months plus one day after surgery. at each evaluation point a mri of the brain with volumetric sequences is performed and clinical data is collected (walking speed and steps for time up and go, 10m walking and 3m walking backwards. mini mental state examination, balance, gait, self rating of incontinence, epworth sleepiness scale). at surgery, all patients are given a ventriculoperitoneal (vp) shunt (strata ® ) with an opening pressure setting of 1.5. after the first evaluation, one month postoperatively, participants are randomized to either a higher (2.5) or a lower (1.0) opening pressure, ratio 1:1. the opening pressure setting is blinded both for patients and the clinician during the subsequent clinical evaluations. at two months, the opening pressure is crossed over to the alternative setting (2.5 or 1.0). at three months, all participants receive the lowest shunt opening pressure (0.5) with the final evaluation the next day. semiautomatic measurement of the lateral as well as the third cerebral ventricles will be performed using the mri scans and volumetric software: symri (syntheticmr ab, linköping, sweden) csf is collected at three times for each participant, from the lumbar spine pre- and 3 months postoperatively and intracranially during surgery. further, intracranial csf is taken through the rickham reservoir at the 3 months postoperative evaluation. after csf from the participants has been collected, a single batch mass spectrometry will be performed with all the samples simultaneously. sample size was determined to achieve 80% power for a two tailed paired t-test for a mean change in ventricular volume of 8ml, estimated from postoperative change in ventricular volume in a previous study. hypotheses: * the volume of the ventricular system in the brain decreases significantly after shunt-surgery. * the ventricular volume is larger at high opening pressures compared to low opening pressures of the shunt. * the decrease in ventricular volume is related to clinical outcome.

Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic normal pressure hydrocephalus and planned treatment with shunt surgery. exclusion criteria: * ongoing anticoagulation treatment * ongoing clopidogrel treatment * mini mental state examination results of 15 or lower. * contraindications to magnetic resonance imaging.

Keywords: ventriculoperitoneal shunt cerebral ventricular volume cerebrospinal fluid
influence of local doxycycline on the outcomes of periodontal regeneration

Conditions: Periodontal Diseases

Summary: in this double-blinded randomized clinical trial, patients presenting periodontal intrabony defects requiring regenerative surgery and showing bop will be included. experimental sites at t-0 will be randomly treated with gentle debridement and administration of local dox (test group) or with debridement alone (control group). after 2 weeks (t-1), defects will be treated by means of minimally invasive surgical technique. 14 days after the surgery (t-2) the ehi will be evaluated by a blinded examiner. patients will be recalled each 2 months up to 12 months (t-3). at t-0, t-1 and t-3 periodontal examination and radiographic analysis will be done.


Eligibility criteria:
inclusion criteria: * 1) diagnosis of stage iii or iv periodontitis (tonetti et al. 2018); * 2) fmps and fmbs \< 15% at the time of enrollment; * 3) etiological periodontal therapy completed at least 3 months prior to screening; * 4) presence of one natural tooth having a vertical defect with residual ppd ≥ 6 mm and a radiographic intrabony component ≥ 3 mm and bop + requiring periodontal regenerative surgery. exclusion criteria: * 1) age \< 18 years; * 2) smoking habits (\> 10 cigarettes/day); * 3) contraindications for periodontal surgery; * 4) systemic diseases affecting periodontal healing; * 5) pregnancy and lactation; * 6) history of periodontal surgery at the experimental teeth; * 7) allergies to doxycycline and tetracyclines; * 8) assumption of antibiotics in the last 3 months.
rasburicase in tumor lysis syndrome

Conditions: Hyperuricemia

Summary: the purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.


Eligibility criteria:
list of inclusion criteria: * acute hyperuricemia patients(uric acid\>8.0 mg/dl) before/during chemotherapy for hematologic malignancies. list of exclusion criteria: * hypersensitivity to uricases or any of the excipients. * known history of hemolytic anemia (g6pd deficiency). the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
an observational study on the relationship between tear metabolomics and pod

Conditions: Postoperative Delirium

Summary: to explore the correlation between tear metabolomics and pod. the purpose of this study was to compare the results of tear metabolomics between pod and non-pod elderly patients undergoing abdominal surgery, to clarify the correlation between tear metabolomics and pod, and to find tear markers related to pod.


Eligibility criteria:
inclusion criteria: * age 65-90 years old; * asa i-iii; * patients who plan to undergo elective abdominal surgery under general anesthesia; * volunteer to participate in this study and sign informed consent. exclusion criteria: * patients with known mental illness or lack of communication or cognitive impairment before operation; * severe vision, hearing, language impairment or other reasons unable to communicate with visitors; * severe dysfunction of important organs such as heart, brain, lung, liver, kidney, etc.; * long-term use of sedatives, antidepressants or alcoholism; * patients with severe postoperative complications and admitted to intensive care unit; * patients who refused or failed to complete the cognitive function test. * patients who could not cooperate with the study for any other reason